Literature DB >> 12969973

Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion.

Andreas Schäfer1, Christian Schulz, Martin Eigenthaler, Daniela Fraccarollo, Anna Kobsar, Meinrad Gawaz, Georg Ertl, Ulrich Walter, Johann Bauersachs.   

Abstract

Chemokines released by the endothelium have proaggregatory properties on platelets. Fractalkine, a recently discovered membrane-bound chemokine with a transmembrane domain, is expressed in vascular injury; however, the effects of fractalkine on platelets have not yet been investigated. Blood was taken from healthy Wistar-Kyoto rats and the expression of the fractalkine receptor on platelets was demonstrated. The modulation of surface expression of P-selectin was assessed by flow cytometry. P-selectin expression was significantly enhanced by in vitro stimulation with recombinant rat fractalkine compared with baseline levels. Selectively inhibiting the function of recombinant fractalkine by an antagonizing antibody or the disruption of the G-protein-coupled intracellular signaling cascade of the fractalkine receptor by pertussis toxin (PTX) completely prevented fractalkine-mediated platelet activation. Preincubation with apyrase significantly attenuated the fractalkine-induced degranulation. In a flow chamber model of platelet adhesion, stimulation with fractalkine significantly enhanced platelet adhesion to collagen and fibrinogen. Similar to P-selectin expression, enhanced adhesion could be prevented by the antagonizing antibody or preincubation of platelets with PTX. Fractalkine, which is overexpressed in atherosclerosis and vascular injury, contributes to platelet activation and adhesion and hence is likely to play a pathophysiologically important role for increased thrombogenesis in vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969973     DOI: 10.1182/blood-2002-10-3260

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias.

Authors:  Stavros Apostolakis; Virginia Amanatidou; Demetrios A Spandidos
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

2.  Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury.

Authors:  Kengo Furuichi; Ji-Liang Gao; Philip M Murphy
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Chebulagic acid inhibits the LPS-induced expression of TNF-α and IL-1β in endothelial cells by suppressing MAPK activation.

Authors:  Yueying Liu; Luer Bao; Liying Xuan; Baohua Song; Lin Lin; Hao Han
Journal:  Exp Ther Med       Date:  2015-04-23       Impact factor: 2.447

4.  Elevated fractalkine in patients with obstructive sleep apnea hypopnea syndrome.

Authors:  Yina Wang; Yayong Li; Ping Chen; Yingquan Luo; Yue Yang; Yu Yang
Journal:  Sleep Breath       Date:  2012-03-01       Impact factor: 2.816

5.  PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1).

Authors:  Bjoern F Kraemer; Oliver Borst; Eva-Maria Gehring; Tanja Schoenberger; Benjamin Urban; Elena Ninci; Peter Seizer; Christine Schmidt; Boris Bigalke; Miriam Koch; Ivo Martinovic; Karin Daub; Tobias Merz; Laura Schwanitz; Konstantinos Stellos; Fabienne Fiesel; Martin Schaller; Florian Lang; Meinrad Gawaz; Stephan Lindemann
Journal:  J Mol Med (Berl)       Date:  2010-09-18       Impact factor: 4.599

6.  Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines.

Authors:  Caroline Cheng; Dennie Tempel; Rien van Haperen; Hetty C de Boer; Dolf Segers; Martin Huisman; Anton Jan van Zonneveld; Pieter J M Leenen; Anton van der Steen; Patrick W Serruys; Rini de Crom; Rob Krams
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

7.  Downregulation of CX3CR1 ameliorates experimental colitis: evidence for CX3CL1-CX3CR1-mediated immune cell recruitment.

Authors:  Felix Becker; Christina Holthoff; Christoph Anthoni; Emile Rijcken; J Steven Alexander; Felicity N E Gavins; H U Spiegel; Norbert Senninger; Thorsten Vowinkel
Journal:  Int J Colorectal Dis       Date:  2016-12-10       Impact factor: 2.571

8.  Integrins αvβ3 and α4β1 act as coreceptors for fractalkine, and the integrin-binding defective mutant of fractalkine is an antagonist of CX3CR1.

Authors:  Masaaki Fujita; Yoko K Takada; Yoshikazu Takada
Journal:  J Immunol       Date:  2012-11-02       Impact factor: 5.422

9.  The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats.

Authors:  A Schäfer; J Pfrang; J Neumüller; S Fiedler; G Ertl; J Bauersachs
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

10.  The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome.

Authors:  Misato Nishimura; Tokiko Nii; Gulzhan Trimova; Shuhei Miura; Kazuo Umezawa; Akira Ushiyama; Tetsuo Kubota
Journal:  J Nephropathol       Date:  2013-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.